書籍詳細

No.1 骨粗鬆症治療のための根拠と服薬指導の基本

P.12 掲載の参考文献

• 1) 司馬正邦ほか:Osteoporosis に対する高カルシウム療法の効果. 整形外科 18:670-678, 1967

• 2) 津山直一ほか:老人性骨粗鬆症に対するエストリオールの効果. -多施設二重盲検法による検討-. 医学のあゆみ 117:470-486, 1981

• 3) 伊丹康人ほか:アルファカルシドールの骨粗籟症に対する効果. 医学のあゆみ 123:958-973, 1982

• 4) Ross PD et al:Bone mass and beyond:risk factor for fractures. Calcif Tissue Int 53(suppl 1):S 134-S 137, 1993

• 5) 折茂 肇ほか:第3回大腿骨頸部骨折全国頻度調査成績. 日本医事新報 3916:46-49, 1999
  Medical*Online

• 6) Margaret E:高齢者の転倒を効率的に防ぐために-ロンドン・キングス大学転倒外来の成果をみる-. Osteroporo Jpn 6:573-578, 1998

• 7) Lauritzen JB et al:Effect of external hip protectors on hip fractures. Lancet 341:11-13, 1993
  pubmed

• 8) Hayashi Y et al:Decrease of vertebral fracture in osteoporotics by administration of 1α-hydroxy-vitamin D3. J Bone and Miner Metab 10:184-188, 1992

• 9) 東京都福祉局総務部計画調整科:高齢者の生活実態(平成7年度東京都社会福祉基礎調査報告書), 1996

P.15 掲載の参考文献

• 1) Suzuki T et al:Genetic and environmental contributions to bone mineral density in Japanese elderly women. Bone 23(suppl):S 269, 1998

• 2) 鈴木隆雄:生活習慣病と骨粗髪症の危険因子およびその共通点. Osteoporo. Jpn 8:13-17, 2000

• 3) Seeman E:Osteoporosis in men. Baillieres Clin Rheumatol 11(Review):613-629, 1997
  pubmed

• 4) 細井孝之:原発性骨粗髪症, 臨床成人病 30:861-864, 2000

• 5) 村木重之ほか:高齢男性の大腿骨頸部骨折患者の危険因子合併率. 2001 (投稿中)

P.18 掲載の参考文献

• 1) Gorai I et al:Early postmenopausal bone loss is prevented by estrogen and partially by 1 alpha-OH-vitamin D 3:therapeutic effects of estrogen and/or 1 alpha-OH-vitamin D 3. Calcif Tissue Int 65:16-22, 1999

• 2) 友光達志ほか:胸・腰椎X線撮影法と骨塩定量法の基準化 dual-energy X-ray absorptiometry (DXA) における骨量の標準定量法と装置の基本性能評価法-. 日本照射技術会雑誌 55:165-187, 1999

• 3) Ravin P et al:High bone turnover is associated with low bone mass in both pre-and postmenopausal women. Bone 19:291-298, 1996

• 4) Garnero P et al:Markers of bone turnover predict postmenopausal forearm bone loss over 4 years:the OFELY study. J Bone Miner Res 14:1614-1621, 1999
  pubmed

• 5) Ross PD:Predicting bone loss and fracture risk with biochemical markers:A review.J Clin Densitom 2:285-294, 1999
  pubmed

• 6) 北谷香代子ほか:エチドロネート周期間歌長期投与の骨粗鬆症に対する治療成績, Osteoporo Jpn 8:242-244, 2000

• 7) Ravin P et al:Biochemical markers can predict the response in bone mass during alendronate treatment in early post menopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237-244, 1999

• 8) Hannon R et al:Response of biochemical markers of bone turnover to hormone replacement therapy:impact of biological variability. J Bone Miner Res 13:1124-1133, 1998
  pubmed

P.21 掲載の参考文献

• 1) 藤井芳夫ほか:オステオポローシスの社会医学的側面. 臨床医 20:1636-1639, 1994

• 2) 小川京子ほか:わが国における骨粗鬆症の Cost-of-illness の推計 (1992年度) . 医療と社会 6:1-15, 1996

• 3) Ray NF et al:Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995:report from the National Osteoporosis Foundation. J Bone Miner Res 12:24-35, 1997

• 4) Feldstein PJ:Health care economics, 5th ed., Delmar Publishers, Albany, 1999

• 5) Phelps CE:Health economics, 2nd ed., Addison-Wesley, Reading, 1997

• 6) 高原亮治:医療経済学と公衆衛生. 公衆衛生 63:4-9, 1999

• 7) 小林廉毅:公衆衛生の経済学ABC. 公衆衛生 63:34-37, 1999

• 8) Drummond MF et al:Methods for economic evaluation Of health care programmes, 2nd ed., Oxford University Press, Oxford, 1997

• 9) 久繁哲徳:最新医療経済学入門, 医学通信社, 東京, 1997

• 10) 武藤孝司:保健医療プログラムの経済的評価法, 篠原出版, 東京, 1998

• 11) 白木正孝:費用対効果からみた骨粗鬆症の問題-臨床医の立場からI-. Clinical Calcium 8:1198-1202, 1998

• 12) Anonymous:Osteoporosis:review of the evidence for prevention, diagnosis and treatment and cost-effective analysis:executive summary. Osteoporos Int 8(suppl 4):S 3-S 6, 1998

• 13) Tosteson AN:Quality of life in the economic evaluation of the osteoporosis prevention and treatment. Spine 22(suppl 24):S 58-S 62, 1997

• 14) Gabriel SE et al:Health-related quality of life in economic evaluation for osteoporosis:whose values should we use? Med Decis Making 19:141-148, 1999

• 15) Tosteson AN et al:Cost effectiveness of screening perimenopausal white women for osteoporosis:bone densitometry and hormone replacement therapy. Ann Intern Med 113:594-603, 1990
  pubmed

• 16) Ankjaer-Jensen A et al:Prevention of osteoporosis:cost-effectiveness of different pharmaceutical treatments. Osteoporos Int 6:265-275, 1996
  pubmed

• 17) Hulley S et al:Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613, 1998
  pubmed

• 18) Torgerson DJ et al:The pharmacoeconomics of hormone replacement therapy. Pharmacoeconomics 16:9-16, 1999
  pubmed

No.2 積極的薬物治療の根拠と服薬指導への反映

P.27 掲載の参考文献

• 1) Anonymous:Consensus development conference 1993:Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94:646-650, 1994

• 2) 太田博明:更年期と生活習慣病. 産婦治療 81:39-43, 2000
  Medical*Online

• 3) 太田博明:生活習慣病-骨粗鬆症. 総合臨床 2000 (in press)

• 4) 太田博明ほか:女性と骨粗鬆症. 産婦治療 78:269-274, 1999
  Medical*Online

• 5) 牧田和也ほか:骨粗鬆症の予防. THE BONE 14:53-58, 2000
  Medical*Online

• 6) Matkovic V et al:J Clin Invest 93:799, 1997

• 7) 太田博明:妊娠と骨粗鬆症-妊娠, 産褥を含めて-. Clinical Calcium 9:93-96, 1999

• 8) 牧田和也ほか:ホルモン補充療法の実際. クリニカ 25:55-60, 1998

• 9) 太田博明ほか:ホルモン補充療法 (HRT) の実際. Geria Med 38:659-664, 2000

• 10) 折茂 肇ほか:骨粗鬆症の治療 (薬物療法) に関するガイドライン. Osteoporos Jpn 6:35-85, 1998

• 11) 折茂 肇ほか:原発性骨粗鬆症の診断基準. Osteoporos JPn 3:111-116, 1995

• 12) 太田博明:Osteoporosis の概念と取り扱いについて-骨粗鬆症治療に関するガイドラインをふまえて-. Osteoporos Jpn 6:757-764, 1998

• 13) 太田博明:カレントレビューホルモン補充療法-長期療法による骨代謝の改善効果と癌のリスク-. 日産婦誌 46:749-763, 1994

• 14) 牧田和也ほか:更年期のエストロゲン補充と骨代謝. ホルモンと臨床 46:87-96, 1998

• 15) 太田博明:骨粗鬆症とホルモン補充療法. 日医会誌 121:810-814, 1999

• 16) 太田博明:老人における骨粗鬆症-閉経後骨粗鬆症との対比から-. 心療内科 4:265-271, 2000

P.31 掲載の参考文献

• 1) 林 泰史:介護保険制度と骨粗鬆症による骨折-ソシオエコノミカルな視点から-. Clinical Calcium 10:391-397, 2000

• 2) 和田誠基:骨粗鬆症の薬物療法. Medicine 35:1081-1083, 1998

• 3) 健康・栄養情報研究会:第六次改定日本人の栄養所要量, 第一出版, 東京, 1999

P.35 掲載の参考文献

• 1) 上原立子, 鈴木康夫:慢性関節リウマチにおける骨粗鬆症. 治療薬 4:93-96, 1999
  Medical*Online

• 2) 鈴木康夫:いまなぜ医療情報が必要なのか. メディカル朝日 6:26-30, 1999

P.38 掲載の参考文献

• 1) Orimo H et al:Trends in the incidence of hip fracture in Japan, 1987-1997:The third nationwide survey. J Bone Miner Metabolism 18:126-131, 2000

• 2) Kitamura S et al:Functional outcome after hip fracture in Japan. Clin Orthop 348:29-36, 1998
  pubmed

• 3) Okuizumi H et al:Effect on the femur of a new hip fracture preventive system using dropped-weight impact testing. J Bone Miner Res 13:1940-1945, 1998
  pubmed

• 4) Lees B et al:Changes in bone density in women starting hormone replacement therapy compared with those in women already established on hormone replacement therapy. Osteoporos Int 5:344-348, 1995
  pubmed

• 5) Devogelaer Jp et al:Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 18:141-150, 1996
  pubmed

• 6) Liberman UA et al:Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Eng J Med 333:1437-1443, 1995

• 7) Tucci JR et al:Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101:488-501, 1996
  pubmed

• 8) Black D et al:The early antifracture efficacy of alendronate in women with osteoporosis:Results from FIT. Osteoporos lnt 11(suppl 2):S 173, 2000

• 9) Seeman E et al:Rapid and sustained effect of risedronate in reducing hip fracture risk in elderly women with osteoporosis. J Bone Miner Res 15(suppl 1):S 149, 2000

• 10) Delmas PD:Do we need to change the WHO definition of osteoporosis? Osteoporos Int 11:189-191, 2000
  pubmed

No.3 骨粗鬆症患者への情報開示と服薬指導への反応

P.44 掲載の参考文献

• 1) Ettinger B et al:Reduction of vertebral fracture risk in postmenopausal women with osteporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 282:637-645, 1999

• 2) Chesnut CH et al:A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis:the prevent recurrence of osteoporotic fracture study. Am J Med 109:267-276, 2000
  pubmed

P.48 掲載の参考文献

• 1) Nakamura T:the importance of generic and nutritional factors in responses to vitamin D and its analogs in osteoporotic patients. Calcif TissueInt 60:119-123, 1997

• 2) Fujita T et al:A three-year comparative trial in osteoporosis treatment:Effect of combined alfacalcidol and elcatonin. J Bone Miner Metab 15:4, 223-226, 1997

• 3) Shiraki M et al:Vitamin K2 (menatetrenone) effectively preventsfractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 15:515-521, 2000

• 4) Miyauchi A et al:Novel ipriflavone receptors coupled to calcium influx regulate osteoclast differentiation and function. Endocrinology 137:3544-3550, 1996
  pubmed

• 5) Liberman UA et al:Effect of oral alendronate on bonemineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443, 1995

• 6) 折茂 肇ほか:骨粗鬆症の治療 (薬物療法) に関するガイドライン. Osteoporo Jpn 6:203-253, 1998

P.51 掲載の参考文献

• 1) Orimo H et al:Osteoporosis, Physical Basis, Assessment and Treatment. ed. by Deluca HF and Mazess R. Elsevier, 1990, pp.223

• 2) Tilyard MW et al:Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357-362, 1992

• 3) Orimo H et al:Reduced occurrence of vertebral crush fracture in senile osteoporosis treated with 1α-hydroxyvitamin D3. Bone Miner 3:47-52, 1987

• 4) 藤田拓男ほか:骨粗鬆症に対するエルカトニンの効果-プラセボを対照薬とした多施設二重盲検比較試験. 医のあゆみ 152:261-282, 1990
  Medical*Online

• 5) Rico H et al:Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 16:131-138, 1992
  pubmed

• 6) 大山直樹ほか:当科における骨粗鬆症の治療について. 市立室蘭医誌 25:3-5, 2000

• 7) Tanizawa T et al:Changes in cortical width with bone turnover in the three different endosteal envelopes of the ilium in postmenopausal osteoporosis. Bone 25:493-499, 1999
  pubmed

• 8) Ettinger B et al:The waning effect of postmenopausal estrogen therapy on osteoporosis. N Engl J Med 329:1192-1193, 1993

P.54 掲載の参考文献

• 1) Lomaestro BM et al:Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. Antimicro Agents and Chemother 35:1004-1007, 1991

• 2) Sahai J et al:The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol 35:302-304, 1993
  pubmed

• 3) 水島 裕ほか編著:今日の治療薬-解説と便覧-, 1996年度, 南江堂, 東京, 1996

• 4) Tougaard L et al:Iatrogenic magnesium intoxication during 1-α-hydroxycholecalciferol treatment. Bri Med J 24:215, 1976

• 5) 林 茂昭ほか:酸化マグネシウムによる高マグネシウム血症により筋脱力をきたした一例. 鹿児島大学医学雑誌 47:221-225, 1996

• 6) Matsuo H et al:A case of hypermagnesemia accompanied accompanied by hypercalcemia induced by a magnesium laxative in an hemodialysis patient. Nephon 71:477-478, 1995

• 7) 石井美佳ほか:メナテトレノン (Ea-0167) の代謝・排泄の検討と吸収に及ぼす食事の影響の検討. 薬理と治療 23:2677-2682, 1995
  Medical*Online

• 8) エーザイ株式会社:骨粗鬆症治療用ビタミンK2剤, グラケーカプセル 15mg (メナテトレノン製剤) . 医薬品インタビューフォーム, 1995, pp.22

• 9) Yamazaki I et al:Effect of ipriflavone on osteoporosis induced by ovariectomy in rats. 日骨代謝会誌 3:205-210, 1986

• 10) Yamazaki I:Effect of ipriflavone on the response of uterus and thyroid to estorgen. Life Sci 38:757-764, 1986

• 11) Takahashi T et al:Elevation of serum theophylline levels by ipriflavone in a patient with chronic obstructive pulmonary disease. Eur J Clin Pharmacol 43:207-208, 1992

• 12) 高橋淳子ほか:テオフィリンの体内動態に及ぼすイプリフ

• 13) 斉藤 満:Ipriflavone (TC 80) のヒトにおける薬物動力学に関する研究. 薬理と治療 13:7223-7233, 1985
  Medical*Online

• 14) Fogelman I et al:Absorption of oral diphosphonate in normal subjects. Clin Endocrinol 24:57-62, 1986
  pubmed

No.4 服薬コンプライアンス低下を招かないための工夫と実践

P.63 掲載の参考文献

• 1) 岡本純明, 桐山健:椎体骨折に続発する変形性脊椎症 (OP-OA-OP 症候群). Clinical Calcium 10:85-90, 2000

• 2) 岡本純明ほか:疾患レビュー「骨粗鬆症」. Suzuken Pharma 1:1-5, 1998

• 3) Lin JH:Bisphosphonates:A Review of Their Pharmacokinetic Properties. Bone 18:75-85, 1996
  pubmed

• 4) 坪井寛ほか:ALENDRONATE 錠 (MK-217/GTH-42) の高齢者女性と非高齢者女性における薬物動態の比較試験. 診断と治療 35:43-49, 1998

• 5) Lichtenstein S et al:致死事象の死亡者数と被験者による推定値との関係. J Exp Psychol[Hum Learn] 4:551-578, 1978

• 6) 西村周三:予防医学と情報化社会. 女性と予防医学:新女性医学大系 Vol.9, (武谷雄二編), 中山書店, 東京, 1998 pp 69-73

• 7) 黒山政―ほか:錠剤・カプセル剤PTPの誤飲の実態とその対策. 薬局 51:1336-1340, 2000
  Medical*Online

• 8) 岡本純明ほか:骨粗鬆症の診断と診療指標の問題点. Modern Physician 20:249-262, 2000

P.66 掲載の参考文献

• 1) Wasnich RD et al:Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236, 2000
  pubmed

• 2) Cummings SR et al:Changes in BMD substantially underestimate the anti-fracture effects of alnedronate and other antiresorptive drugs (Abstract). J Bone Miner Res 11:S 102, 1996

• 3) Delmas PD:How does antiresorptive therapy decrease the risk offracture In women with osteoporosis? Bone 27:1-3, 2000

• 4) Ravn P et al:Alendronate in early postmenopausal women:effects on bone mass during long-term treatment and after withdrawal. J Clin Endocrinol Metab 85:1492-1497, 2000

• 5) Tanizawa T et al:Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures:a retrospective study. Osteoporos Int 9:163-170, 1999
  pubmed

P.74 掲載の参考文献

• 1) Black DM et al:Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541, 1996
  pubmed

• 2) Gerz BJ et al:Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58:288-298, 1995

• 3) De Greon PC et al:Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1021, 1996

• 4) Shiraki M et al:A double-masked multicenter conparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporosis Int 9:183-192, 1999

• 5) Schnitzler T et al:Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 12:1-12, 2000

No.5 骨粗鬆症のタイプと病態に応じた治療設計・服薬指導の工夫

P.78 掲載の参考文献

• 1) 折茂 肇ほか:原発性骨粗鬆症の診断基準. 日本骨代謝学会雑誌 18:76-82, 2000
  Medical*Online

• 2) 折茂 肇ほか:骨粗鬆症の治療 (薬物療法) に関するガイドライン:Osteoporosis Japan 6:205-253, 1998

• 3) 日本骨粗鬆症学会:骨粗鬆症診療における骨代謝マーカーの適正使用に関する指針検討委員会. Osteoporosis Japan 9:255-307, 2001

P.85 掲載の参考文献

• 1) 折茂 肇ほか:原発性骨粗鬆症の診断基準 (1996年度改訂版) . Osteoporosis Japan 4:643653, 1996

• 2) Okano H et al:The long term effect of menopause on postmenopausal bone loss in Japanese women:Results from a prospective study. J Bone Miner Res 13:303-338, 1998

• 3) 杉本 修ほか:本邦婦人における退行期骨粗鬆症予防のための管理方式. 日本産科婦人科学会雑誌 45:603-614, 1993

• 4) 太田博明:Osteopeniaの概念と取り扱いについて-骨粗鬆症治療に関するガイドラインをふまえて-. Osteoporosis Japan 6:757 764. 1998

• 5) Guidelines for counseling postmenopausal women about preventive hormone therapy:American College of Medicine. Ann Intern Med 117:1038 1041, 1992

• 6) Collaborative Group on Hormonal Factors in Breast Cancer:Breast cancer and hormone replacement therapy:collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350:1047 1059, 1997

• 7) Mizunuma H et al:Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy:a 2 year prospective study. Maturitas 27:6976, 1997

P.88 掲載の参考文献

• 1) Pentecost RL et al:Fatigue, insufficiency, and pathokogic fractures. JAMA 187:1001-1004, 1964
  pubmed

• 2) 渡辺惣兵衛ほか:Insufficiency fracture-その定義と重要性, 整災外 40:213-217, 1997

• 3) Mink JH et al:Occult cartilage and bone injuries of the knee;detection, classification, and assessment with MR imaging. Radiology 170:823-829, 1989
  pubmed

• 4) Yao L et al:Occult interosseous fracture;detection with MR imazing. Radiology 167:749-751, 1988

• 5) 中野哲雄ほか:新鮮脊椎圧迫骨折の単純X線像による正診率. 骨折 21:586-588, 1999
  Medical*Online

• 6) Ohishi T et al:Changes of biochemical markers during fracture healing. Arch Orthop Trauma Surg 118:126-130, 1998
  pubmed

• 7) Ingle BM et al:Changes in Bone Mass and Bone Turnover Following Distal Forearm Fracture. Osteoporosis Int 10:399-407, 1999
  pubmed

No.6 続発性骨粗鬆症患者の骨量減少への治療戦略と服薬指導のポイント

P.93 掲載の参考文献

• 1) Adinoff AD et al:Steroid-induced fractures and bone loss in patients with anthma. NEJM 309:265-268, 1983
  pubmed

• 2) Cooper C et al:Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 54:49-52, 1995
  pubmed

• 3) American College of Rheumatology Task Force on Osteoporosis Guidelines:Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Rheum 39:1791-1801, 1996
  pubmed

• 4) Eastel R et al:AUK concenssus group on management of glucocorticoid-induced osteoporosis:an update. J Intern Med 244:271-292, 1998

• 5) Sambrook PN et al:Determinants of axial bone loss in rheumatoid arthritis Rheum 30:721-728, 1987
  pubmed

• 6) Miyamoto S et al:Effects of glucocorticoids on bone mineral density in rheumatoid arthritis. Arch Orthop Trauma Surg 119:18-21, 1999

• 7) Locascio V et al:Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8:39-51, 1990

P.96 掲載の参考文献

• 1) 五來逸雄:加齢による骨代謝の変化とエストロゲンの生理学的意義に関する研究. 日産婦誌 49:537-545, 1997

• 2) 杉本修ほか:生殖・内分泌委員会報告 (本邦婦人における退行期骨粗鬆症予防のための管理方式). 日産婦誌 45:603- 614, 1993

• 3) Rosen CJ et al:The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 82:1904-1910, 1997
  pubmed

• 4) Cooper C et al:Matrix delivery transdermal 17β-stradiol for the prevention of bone loss in postmenopausal women. Osteoporosis Int 9:358-366, 1996

P.99 掲載の参考文献

• 1) Albright F et al:Parathyroid glands and metabolic bone disease. Selected studies, Williams and Wilkins, Baltimore, 1948, pp.150

• 2) 井村裕夫ほか:糖尿病性骨減少症に関する疫学調査 (第1報) . 糖尿病 30:921-928, 1987

• 3) 鈴木 清ほか:糖尿病と骨代謝異常-最近の考え方と問題点-. 栄養学雑誌 57:125-134, 1999

• 4) 滝澤 誠ほか:糖尿病性骨減少症-その病態と病因. Clinical Calcium 9:922-925, 1999

• 5) Inaba M et al:Influence of high glucose on 1,25 dihydroxyvitamin D3-induced effect on human osteoblastic MG-63 cells. J Bone Miner Res 10:1050-1056, 1995

• 6) Yoshida O et al:Impaired response of human osteosarcoma (MG-63) cells to human parathyroid hormone induced by sustain exposure to high glucose. Miner electrolyte Metab 21:201-204, 1995
  pubmed

• 7) Ogata N et al:Insulin receptor substrate-1 in osteoblast is indispensable for maintaing bone turnover. J Clin Invest 105:935-943, 2000

• 8) Williams JP et al:Regeulation of osteoclastic bone resorption by glucose. Biochem Biophys Res Comm 235:646-651, 1997
  pubmed

• 9) 石田 均ほか:糖尿病患者に発症した骨減少症. 治療 78:3437-3443, 1996
  Medical*Online

P.103 掲載の参考文献

• 1) Albright F et al:The parathyroid glands and metabolic bone disease:Selected Studies. Baltimore, Williams and Wilkins, 1948, p 162

• 2) 三木隆己ほか:骨粗鬆症治療の最近の進歩, 薬効の判定, THE BONE 14, 109-113, 2000

• 3) Kenneth GS et al:Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis. N Eng J Med 337:382-387, 1997

• 4) Kenneth GS et al:Alendronate for the prevention and treatment of corticosteroid induced osteoporosis. N Eng J Med 339:292-299, 1998